Zongertinib (Hernexeos) 60mg | Germany Originator HER2 Inhibitor for NSCLC | GLT
Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.
- We reply within 24 hours with pricing, availability & COA
- Serves individuals and institutions worldwide
Prefer email? [email protected] · +86 15234153837
Generic Information: Hernexeos (Zongertinib) — Germany Originator Version
Hernexeos is the originator brand of zongertinib, developed and manufactured by Boehringer Ingelheim, a research-driven pharmaceutical company headquartered in Germany. Zongertinib is recognised as the first oral HER2 tyrosine kinase inhibitor to reach the market for HER2-mutant non-small cell lung cancer. The Germany originator version is supplied as 60 mg × 60 tablets per bottle.
This is the reference product against which all other zongertinib versions are compared. It received accelerated approval in the United States for HER2-mutant NSCLC and has been authorised in additional markets. For patients who prefer the originator molecule with the longest-established clinical dataset, the Germany originator version of Hernexeos represents the standard-of-care reference in this emerging molecular indication.
What Is Hernexeos?
Hernexeos is an oral, once-daily tablet of zongertinib. It belongs to the kinase inhibitor class and is specifically a HER2 (ERBB2) inhibitor. The product is supplied as 60 mg film-coated tablets, with a 60-tablet bottle as the standard pack. As an oral therapy, it offers patients a convenient alternative to intravenous cancer treatments and can be taken at home under medical supervision.
How Does Hernexeos (Zongertinib) Work?
Zongertinib exerts its effect by selectively inhibiting the HER2 tyrosine kinase. In tumours carrying HER2 (ERBB2) tyrosine kinase domain activating mutations, this receptor drives continuous growth signalling; zongertinib blocks that signal, slowing or halting tumour growth. Its molecular design favours inhibition of the mutant HER2 over wild-type EGFR, which is intended to improve the therapeutic window and reduce certain class-related toxicities.
Indications
Hernexeos is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumours have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorised or otherwise validated test. The initial approval was granted under accelerated approval based on objective response rate and duration of response, in patients who had progressed after prior systemic therapy.
Dosage
Dosing is weight-based. Adults weighing less than 90 kg receive 120 mg once daily, and those weighing 90 kg or more receive 180 mg once daily, each taken as 60 mg tablets. A 60-tablet bottle provides a month of therapy for patients under 90 kg. Treatment continues until disease progression or unacceptable toxicity, with dose modifications managed by the oncology team.
Side Effects
The most frequent adverse reactions include diarrhoea, rash, stomatitis, decreased appetite, fatigue, and elevated liver enzymes. Nausea and anaemia may also occur. Most side effects are mild to moderate and manageable, but liver function and other parameters may need periodic monitoring. Patients should promptly report persistent diarrhoea, rash, jaundice, or unusual fatigue to their healthcare provider.
Storage
Store Hernexeos at room temperature in the original bottle, away from moisture, heat, and light. Keep the container tightly sealed and out of reach of children. Check the expiry date before use and retain packaging for batch and source traceability.
Why Choose the GLT?
GLT is a Hong Kong-licensed pharmaceutical wholesaler that helps patients and institutions access originator and generic oncology medicines through reliable channels. When you choose GLT to source Hernexeos, you benefit from verified supply chains, clear documentation, and responsive support for cross-border orders. We work with both individual patients and institutional buyers, providing guidance on prescription requirements, availability, and delivery while keeping sourcing transparent and traceable.
How to Order Hernexeos (Germany Originator)
To order the Germany originator version of Hernexeos, contact GLT through the details below. A valid prescription and HER2 mutation confirmation are required. Our team will advise on availability, documentation, and shipping for individual or institutional orders.
WhatsApp: +86 15234153837 | Email: [email protected]
FAQ
What is zongertinib used for? Zongertinib is used to treat adult patients with unresectable or metastatic non-squamous non-small cell lung cancer that carries a HER2 (ERBB2) tyrosine kinase domain activating mutation, after prior systemic therapy.
Is Hernexeos a first-in-class drug? Yes, zongertinib is considered the first oral HER2 tyrosine kinase inhibitor approved for HER2-mutant NSCLC, a molecular subtype that previously lacked a dedicated oral targeted therapy.
What is the brand name of zongertinib? The brand name is Hernexeos; in China it is marketed as 圣赫途. It is developed by Boehringer Ingelheim.
What dose of zongertinib is recommended? The recommended dose is 120 mg once daily for patients under 90 kg and 180 mg once daily for patients 90 kg or more.
Is there a generic version of zongertinib? In some regions, generic versions such as LuciZonger (Laos) are available. Both contain the same active ingredient, zongertinib.